NQO1 and chronic obstructive pulmonary disease: Nrf2 activators caused significant dose-dependent increases of NQO1 mRNA expression and NQO1 activity in alveolar macrophages from COPD patients (Fig. 4A and C, respectively) and S (Fig. 4B and D, respectively).